CTLA4 and metastatic melanoma: This study validates the antitumor activity of the combination of pembrolizumab and lenvatinib in real-world patients with metastatic melanoma with confirmed progression on previous anti-PD-1/CTLA-4 therapy and shows for first time the superiority of this combination over chemotherapy.